Metabolic reprogramming in mutant IDH1 glioma cells

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Izquierdo Garcia, Jose L ^a   Viswanath, Pavithra ^a   Eriksson, Pia ^a   Chaumeil, Myriam M ^a   Pieper, Russell O ^a,b   Phillips, Joanna J ^a,b   Ronen, Sabrina M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; GLUTAMIC ACID; ISOCITRATE DEHYDROGENASE 1; LACTIC ACID; LENTIVIRUS VECTOR; PHOSPHORYLCHOLINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

AMINO ACID METABOLISM; ARTICLE; ASTROCYTE; CELL CYCLE ASSAY; CELL METABOLISM; CELL MUTANT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IDH1 GENE; IMMORTALIZED CELL LINE; METABOLITE; METABOLOME; METABOLOMICS; MUTATIONAL ANALYSIS; NUCLEAR REPROGRAMMING; PRINCIPAL COMPONENT ANALYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; WESTERN BLOTTING; WILD TYPE; BRAIN TUMOR; ENZYMOLOGY; METABOLISM; MUTATION;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 84923291261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118781     Document Type: Article

References (40)

1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2Mutations in Gliomas. New Engl J Med. 2009; 360: 765-773. doi: 10.1056/NEJMoa0808710 PMID: 19228619
2. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. New Engl J Med. 2009; 361: 1058-1066. doi: 10.1056/NEJMoa0903840 PMID: 19657110
3. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011; 43: 1262-1265. doi: 10.1038/ng.994 PMID: 22057236
4. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19: 764-772. doi: 10.1158/1078-0432.CCR-12-3002 PMID: 23209033
5. Yang H, Ye D, Guan K- L, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012; 18: 5562-5571. doi: 10.1158/1078-0432.CCR-12-1773 PMID: 23071358
6. Losman J- A, Kaelin WG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Development. 2013; 27: 836-852.
7. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462: 739-744. doi: 10.1038/nature08617 PMID: 19935646
8. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17: 225-234. doi: 10.1016/j.ccr.2010.01.020 PMID: 20171147
9. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19: 17-30. doi: 10.1016/j.ccr.2010.12.014 PMID: 21251613
10. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483: 479-483. doi: 10.1038/nature10866 PMID: 22343889
11. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. PNAS. 2011; 108: 3270-3275. doi: 10.1073/pnas.1019393108 PMID: 21289278
12. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HAI, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012; 4: 116ra115.
13. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004; 4: 551-561. PMID: 15229480
14. Peet AC, McConville C, Wilson M, Levine BA, Reed M, Dyer SA, et al. 1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines. NMR Biomed. 2007; 20: 692-700. PMID: 17506115
15. Lodi A, Tiziani S, Khanim FL, Drayson MT, Gunther UL, Bunce CM, et al. Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. ACS Chem Biol. 2011; 6: 169-175. doi: 10.1021/cb900300j PMID: 20886892
16. Lodi A, Ronen SM. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS ONE. 2011; 6: e26155. doi: 10.1371/journal.pone.0026155 PMID: 22022547
17. Lindon JC, Holmes E, Nicholson JK. Pattern recognition methods and applications in biomedical magnetic resonance. Prog Nucl Mag Res Sp. 2001; 39: 1-40.
18. Izquierdo-Garcia JL, Villa P, Kyriazis A, del Puerto-Nevado L, Pérez-Rial S, Rodriguez I, et al. Descriptive review of current NMR-based metabolomic data analysis packages. Prog Nucl Mag Res Sp. 2011; 59: 263-270.
19. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 2001; 61: 4956-4960. PMID: 11431323
20. Chaumeil MM, Larson PEZ, Yoshihara HAI, Danforth OM, Vigneron DB, Nelson SJ, et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun. 2013; 4: 2429. doi: 10.1038/ncomms3429 PMID: 24019001
21. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer. 2001; 84: 691-696. PMID: 11237392
22. Izquierdo-García JL, Rodriguez I, Kyriazis A, Villa P, Barreiro P, Desco M, et al. A novel R-package graphic user interface for the analysis of metabonomic profiles. BMC Bioinformatics. 2009; 10: 363. doi: 10.1186/1471-2105-10-363 PMID: 19874601
23. Xi Y, Rocke DM. Baseline correction for NMR spectroscopic metabolomics data analysis. BMC Bioinformatics. 2008; 9: 324. doi: 10.1186/1471-2105-9-324 PMID: 18664284
24. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Introduction to multi- and megavariate data analysis using projection methods (PCA & PLS). Umetrics; 1999.
25. Morrison DF. Multivariate statistical methods. New York,: McGraw-Hill; 1967 xiii, 338 p. p.
26. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0 - The Human Metabolome Database in 2013. Nucleic Acids Res. 2013; 41: D801-807. doi: 10.1093/nar/gks1065 PMID: 23161693
27. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483: 474-U130. doi: 10.1038/nature10860 PMID: 22343901
28. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem (Palo Alto Calif). 2008; 1: 45-69. doi: 10.1146/annurev.anchem.1.031207.113026 PMID: 20636074
29. Cuperlovic-Culf M. Nmr metabolomics in cancer research. Philadelphia, PA: Woodhead Pub.; 2013.
30. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem. 2007; 387: 525-527. PMID: 16955259
31. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012; 18: 624-629. doi: 10.1038/nm.2682 PMID: 22281806
32. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012; 4: 116ra114.
33. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012; 107: 197-205. doi: 10.1007/s11060-011-0737-8 PMID: 22015945
34. Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, et al. Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma. Cancer Res. 2014; 74: 4247-4257. doi: 10.1158/0008-5472.CAN-14-0680 PMID: 24876103
35. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med. 2013; 19: 901-908. doi: 10.1038/nm.3217 PMID: 23793099
36. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro-Oncology. 2014; 16: 686-695. doi: 10.1093/neuonc/not243 PMID: 24366912
37. Kennedy EP. The biological synthesis of phospholipids. Can J Biochem Physiol. 1956; 34: 334-348. PMID: 13304754
38. Billah MM, Anthes JC. The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem J. 1990; 269: 281-291. PMID: 2201284
39. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011; 11: 835-848. doi: 10.1038/nrc3162 PMID: 22089420
40. Righi V, Roda JM, Paz J, Mucci A, Tugnoli V, Rodriguez-Tarduchy G, et al. 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed. 2009; 22: 629-637. doi: 10.1002/nbm.1377 PMID: 19322812